Compare Marsh & McLennan Companies, Inc. (MRSH) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs Smith & Nephew plc — how do they compare? Marsh & McLennan Companies, Inc. trades at $176.15 (market cap $84.31B), while Smith & Nephew plc trades at $27.14 (market cap $11.10B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 7.6× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Marsh & McLennan Companies, Inc. for 109 Days and Smith & Nephew plc for 120 Days on average.
| MRSH | SNN | |
|---|---|---|
Market Cap | $84.31B | $11.10B |
Volume | 3,948,947 | 1,051,703 |
Sector | Financials | Health |
52-Week High | $207.02 | $37.17 |
52-Week Low | $157.32 | $26.42 |
Typical Hold Time | 109 Days | 120 Days |
Enterprise Value | $104.99B | $14.13B |
Dividend Yield | 2.24% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh (MRSH) trades at $173.66, up 1.11% today, with a bullish technical signal despite mixed moving averages and oscillators. The company shows strong fundamentals, with revenue growing to $26.98B in 2025 and net income of $4.16B, supported by consistent earnings beats. Recent news highlights the completion of the Accel Holdings acquisition, potentially enhancing its advisory services footprint. Valuation ratios include a P/E of 21.57 and ROE of 25.72%, indicating solid profitability.
The outlook for MRSH is positive, driven by earnings momentum and strategic acquisitions, but risks include high debt levels and competitive pressures. Analysts maintain a consensus price target of $202.71, suggesting upside potential, though the majority recommend Hold. Investors should weigh growth opportunities against execution risks and market volatility.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
